|
|
Volumn 3, Issue 7, 2013, Pages
|
|
PD-1 inhibitor becomes "Breakthrough Therapy"
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IPILIMUMAB;
LAMBROLIZUMAB;
MK 3475;
MONOCLONAL ANTIBODY;
NIVOLUMAB;
PROGRAMMED DEATH 1 LIGAND 1;
PROGRAMMED DEATH 1 RECEPTOR;
UNCLASSIFIED DRUG;
ARTICLE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNE RESPONSE;
KIDNEY CARCINOMA;
LUNG NON SMALL CELL CANCER;
METASTATIC MELANOMA;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
SOLID TUMOR;
|
|
EID: 85047655952
PISSN: 21598274
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2013-074 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|